Diplomat dispensing Mavyret
FLINT, Mich. — Diplomat Pharmacy is dispensing a newly approved treatment for chronic hepatitis C. The company on Friday announced that it is now dispensing AbbVie’s Mavyret (glecaprevir and pibrentasvir) tablets.
The drug is indicated to treat patients with all major genotypes of chronic hepatitis C infection with cirrhosis or with compensated cirrhosis. It also is also indicated for adults with Genotype 1 infection who previously have been treated with a regimen containing an NS5A inhibitor or an NS3/4A protease inhibitor (but not both).
“We are proud to expand upon Diplomat’s therapy offerings to patients who have been diagnosed with chronic hepatitis C,” said Joel Saban, president of Diplomat. “This valuable treatment option gives more patients the possibility of a life without this serious disease.”
FDA approves Pfizer’s leukemia drug Besponsa
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug from Pfizer, Besponsa (inotuzumab ozogamicin). The drug is indicated to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or ALL.
"For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "These patients have few treatments available and today's approval provides a new, targeted treatment option."
B-cell precursor ALL is a rapidly progressing type of cancer in which a patient’s bone marrow makes too many of an immature type of white blood cell. The National Cancer Institute estimates that roughly 5,970 people will be diagnosed with it this year, and that 1,440 will die from the illness.
“Besponsa will help address a significant need for new treatment options in B-cell acute lymphoblastic leukemia, and may help more patients reach stem cell transplant, which provides the best chance for long term remission,” Pfizer Oncology global president Liz Barrett said. “We’re proud to build on our continued commitment to patients with hematologic malignancies, and will continue our work to find new treatments in acute lymphoblastic leukemia and other blood cancers.”
Kroger promotes flu shots and giving back through One Shot, One Meal initiative
CINCINNATI — Kroger on Thursday announced its second annual health and wellness campaign, One Shot, One Meal, in partnership with The Little Clinic and Feeding America. From Aug. 17 through April 1, 2018, Kroger will donate one meal through the Feeding America network of food banks for every flu shot administered at all Kroger family of pharmacies and The Little Clinic locations.
"Kroger is committed to helping people live healthier lives and we're excited to continue this initiative for the second year," stated Colleen Lindholz, Kroger's president of pharmacy and The Little Clinic. "When you receive the flu shot this season at any of the Kroger family of pharmacies or The Little Clinic locations, you will help protect your health and provide a meal for a neighbor struggling with hunger. Kroger donated 330 million meals in 2016, and last year's campaign helped us achieve this milestone. We know that meals matter because nutrition is a key aspect of building healthier communities."
"Feeding America aims to provide wellness, nourishment and strength to people facing hunger," said Diana Aviv, CEO of Feeding America. "We are excited to partner with Kroger for the second year on this health and wellness campaign. Visionary partners like Kroger enable us to help the 46 million Americans who receive food and groceries from our network of food banks."